Sun Pharma has announced that its US subsidiaries Taro Pharmaceuticals USA and Sun Pharmaceutical Industries Inc. have struck a deal that will see the pair pay out $85m to settle generic price-fixing allegations.
Sun and Taro “have signed settlement agreements with the direct purchaser plaintiffs in the generic pharmaceuticals pricing antitrust litigation that has been taking place in the Eastern District of Pennsylvania,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?